Open access
Aug 2026
The CA19-9 glycan is a viable target for CAR T cell therapy in pancreatic and other solid tumors.
The findings demonstrate the effectiveness of CA19-9 CAR T cells in GI cancers using various pre-clinical tumor models, providing a rationale for further clinical development.
Fei-Yan Mo, Austin L. Good, Jayne C. McDevitt et al.
· Gastroenterology · 0 citations